Risk factors differ based on sex and race and ethnicity
Individualized multidomain interventions equally effective for improving cognition in women, men
Presence of Alzheimer disease pathology related to Stages of Objective Memory Impairment in cognitively unimpaired older adults
Less than one-quarter of older adults report they would want to take it
Associations consistent across different psychiatric conditions, for Alzheimer disease and all other dementias
Announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year
The Self-Administered Gerocognitive Examination detects the conversion from mild cognitive impairment to dementia sooner than the MMSE
Drug shows promise in clearing brain plaques believed to play a role in Alzheimer disease
Amyloid-related imaging abnormalities-edema seen on brain MRI most common adverse event in participants receiving high-dose aducanumab
Grounds insufficient to offer aducanumab for moderate, advanced Alzheimer dementia or patients without biomarker evidence of brain ß-amyloid